1.315
price down icon11.15%   -0.165
after-market 시간 외 거래: 1.32 0.005 +0.38%
loading
전일 마감가:
$1.48
열려 있는:
$1.365
하루 거래량:
1.74M
Relative Volume:
0.64
시가총액:
$270.69M
수익:
$314.00K
순이익/손실:
$-40.23M
주가수익비율:
-4.6964
EPS:
-0.28
순현금흐름:
$-84.71M
1주 성능:
-16.24%
1개월 성능:
-12.33%
6개월 성능:
+24.06%
1년 성능:
-44.98%
1일 변동 폭
Value
$1.31
$1.41
1주일 범위
Value
$1.22
$1.57
52주 변동 폭
Value
$1.03
$2.85

Atai Life Sciences N V Stock (ATAI) Company Profile

Name
명칭
Atai Life Sciences N V
Name
전화
49 89 2153 9035
Name
주소
WALLSTRASSE 16, BERLIN
Name
직원
54
Name
트위터
Name
다음 수익 날짜
2024-12-11
Name
최신 SEC 제출 서류
Name
ATAI's Discussions on Twitter

ATAI을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ATAI
Atai Life Sciences N V
1.315 270.69M 314.00K -40.23M -84.71M -0.28
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 125.55B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 67.78B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 36.24B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.99B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.77B 3.81B -644.79M -669.77M -6.24

Atai Life Sciences N V Stock (ATAI) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-11-18 재확인 H.C. Wainwright Buy
2024-04-03 업그레이드 Maxim Group Hold → Buy
2022-11-01 개시 Loop Capital Buy
2021-11-30 개시 Maxim Group Buy
2021-11-11 개시 ROTH Capital Buy
2021-10-18 개시 H.C. Wainwright Buy
2021-09-01 개시 Jefferies Buy
2021-07-13 개시 Berenberg Buy
2021-07-13 개시 Canaccord Genuity Buy
2021-07-13 개시 Cantor Fitzgerald Buy
2021-07-13 개시 Citigroup Buy
2021-07-13 개시 Cowen Outperform
2021-07-13 개시 Credit Suisse Outperform
2021-07-13 개시 RBC Capital Mkts Sector Perform
2021-07-08 개시 Aegis Capital Buy
모두보기

Atai Life Sciences N V 주식(ATAI)의 최신 뉴스

pulisher
Mar 31, 2025

How Are Things Looking For ATAI Life Sciences N.V (NASDAQ: ATAI) For The Short Term? - stocksregister.com

Mar 31, 2025
pulisher
Mar 25, 2025

Atai Life Sciences CEO Rao Srinivas sells $101,814 in common shares - Investing.com Australia

Mar 25, 2025
pulisher
Mar 24, 2025

Atai Life Sciences CEO Rao Srinivas sells $101,814 in common shares By Investing.com - Investing.com South Africa

Mar 24, 2025
pulisher
Mar 24, 2025

Atai Life Sciences chief scientific officer sells $17,767 in shares By Investing.com - Investing.com South Africa

Mar 24, 2025
pulisher
Mar 24, 2025

Atai life sciences CMO Craig James sells $15,610 in shares By Investing.com - Investing.com South Africa

Mar 24, 2025
pulisher
Mar 24, 2025

Atai Life Sciences chief business officer sells $65,560 in stock By Investing.com - Investing.com South Africa

Mar 24, 2025
pulisher
Mar 24, 2025

Atai Life Sciences chief business officer sells $65,560 in stock - Investing.com India

Mar 24, 2025
pulisher
Mar 24, 2025

Atai Life Sciences chief scientific officer sells $17,767 in shares - Investing.com India

Mar 24, 2025
pulisher
Mar 24, 2025

Atai Life Sciences CFO sells shares worth $45,285 - Investing.com India

Mar 24, 2025
pulisher
Mar 24, 2025

Atai life sciences CMO Craig James sells $15,610 in shares - Investing.com India

Mar 24, 2025
pulisher
Mar 24, 2025

Atai Life Sciences director Angermayer buys $2.52 million in shares By Investing.com - Investing.com UK

Mar 24, 2025
pulisher
Mar 24, 2025

Atai Life Sciences director Angermayer buys $2.52 million in shares - Investing.com

Mar 24, 2025
pulisher
Mar 21, 2025

Psychedelic: atai Life Sciences, NRx report quarterly results - Yahoo Finance

Mar 21, 2025
pulisher
Mar 21, 2025

Nasdaq-Listed Biotech Firm Atai Life Sciences to Launch Bitcoin Treasury Strategy - Cryptonews

Mar 21, 2025
pulisher
Mar 20, 2025

ATAI Life Sciences invests $5M in Bitcoin as reserve asset By Investing.com - Investing.com Australia

Mar 20, 2025
pulisher
Mar 17, 2025

atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights - The Manila Times

Mar 17, 2025
pulisher
Mar 13, 2025

Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial - TipRanks

Mar 13, 2025
pulisher
Mar 11, 2025

atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression - Yahoo Finance

Mar 11, 2025
pulisher
Mar 04, 2025

Is Atai Life Sciences N.V. (ATAI) Among Stocks With At Least $20 Million In Insider Spending Recently? - Insider Monkey

Mar 04, 2025
pulisher
Mar 04, 2025

10 Stocks With At Least $20 Million In Insider Spending Recently - Insider Monkey

Mar 04, 2025
pulisher
Mar 03, 2025

How is ATAI’s stock performing after recent trades? - US Post News

Mar 03, 2025
pulisher
Mar 01, 2025

Atai Life Sciences N.V. (ATAI): Among the Best Psychedelic Stocks to Buy in 2025 - Insider Monkey

Mar 01, 2025
pulisher
Feb 28, 2025

12 Best Psychedelic Stocks to Buy in 2025 - Insider Monkey

Feb 28, 2025
pulisher
Feb 28, 2025

ATAI’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle

Feb 28, 2025
pulisher
Feb 27, 2025

Atai: Following The Path That Spravato Laid And Moving Beyond It - Seeking Alpha

Feb 27, 2025
pulisher
Feb 25, 2025

Comprehensive Market Analysis of Latest Published Different Types of Depression Reports | DelveInsight - GlobeNewswire Inc.

Feb 25, 2025
pulisher
Feb 24, 2025

atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference - Yahoo Finance UK

Feb 24, 2025
pulisher
Feb 23, 2025

Biotechs Highlight 6 Stocks Insiders Are Buying Now - 24/7 Wall St.

Feb 23, 2025
pulisher
Feb 20, 2025

Atai Life Sciences Raises $63.3 Million After Closing Public Offering -February 20, 2025 at 10:10 am EST - Marketscreener.com

Feb 20, 2025
pulisher
Feb 20, 2025

atai Life Sciences completes public offering, raising $63.25M - Proactive Investors UK

Feb 20, 2025
pulisher
Feb 20, 2025

atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares - Yahoo Finance UK

Feb 20, 2025
pulisher
Feb 19, 2025

Apeiron Investment Group purchases $22.8m in ATAI Life Sciences shares By Investing.com - Investing.com Australia

Feb 19, 2025
pulisher
Feb 19, 2025

Drug developers struggle in 2024; Fibrogen, Acadia, Atai post gains - BioWorld Online

Feb 19, 2025
pulisher
Feb 13, 2025

atai Life Sciences announces pricing of $55M public offering of shares - Proactive Investors UK

Feb 13, 2025
pulisher
Feb 13, 2025

Trade Desk Posts Downbeat Revenue, Joins Aspen Aerogels, Fastly And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga

Feb 13, 2025
pulisher
Feb 13, 2025

Atai Life Sciences Prices $55 Million Stock Offering -February 13, 2025 at 04:47 am EST - Marketscreener.com

Feb 13, 2025
pulisher
Feb 12, 2025

ATAI Life Sciences Secures Massive $55M War Chest for Breakthrough Mental Health Treatments - StockTitan

Feb 12, 2025
pulisher
Feb 12, 2025

atai Life Sciences Announces Pricing of Public Offering of Common Shares - Yahoo Finance

Feb 12, 2025
pulisher
Feb 12, 2025

atai Life Sciences unveils $55M public offering to advance mental health treatments - Proactive Investors USA

Feb 12, 2025
pulisher
Feb 12, 2025

atai Life Sciences Secures Major Funding: $55M Share Offering to Revolutionize Mental Health Treatment Pipeline - StockTitan

Feb 12, 2025
pulisher
Feb 11, 2025

Atai CEO Rao optimistic about psychedelic therapies despite Lykos setback (ATAI:NASDAQ) - Seeking Alpha

Feb 11, 2025
pulisher
Feb 10, 2025

Evaluating ATAI’s financial ratios for a profitable investment - US Post News

Feb 10, 2025
pulisher
Feb 10, 2025

Get in on ATAI Life Sciences N.V’s (ATAI) buy-in window today! - SETE News

Feb 10, 2025
pulisher
Feb 08, 2025

atai Life Sciences CEO discusses success of BPL-003 alcohol use disorder trialICYMI - Proactive Investors USA

Feb 08, 2025
pulisher
Feb 07, 2025

ATAI Life Sciences N.V (NASDAQ: ATAI) Has Succeeded In Attracting Investors This Year, The Stock Is Up 59.40% Year-To-Date – Marketing Sentinel - Marketing Sentinel

Feb 07, 2025
pulisher
Feb 06, 2025

atai Life Sciences-backed psychedelic drug could offer superior value, analysts believe - Proactive Investors USA

Feb 06, 2025
pulisher
Feb 04, 2025

ATAI’s price-to-cash ratio: How it affects the stock’s valuation. - US Post News

Feb 04, 2025

Atai Life Sciences N V (ATAI) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
자본화:     |  볼륨(24시간):